Safety and tolerability of the combination of veltuzumab and epratuzumab with intensive chemotherapy in patients with relapsed B-cell acute lymphoblastic leukaemia (ALL)
Acute lymphoblastic leukaemia (ALL) is a fast-growing cancer of the white blood cells. Standard chemotherapy can successfully put the cancer into remission, but sometimes the leukaemia returns. When this happens, doctors need better ways to treat it. This trial is testing two targeted antibody treatments, called veltuzumab and epratuzumab. These drugs are designed to attach to specific markers on leukaemia cells, helping the body recognize and attack the cancer. Researchers want to see if combining these antibodies with strong, standard chemotherapy is safe, well-tolerated, and effective. The trial is open to people aged 16 to 65 who have a first recurrence of B-cell ALL after at least six months of remission. Participants are monitored closely to find the safest doses, watch for side effects, and see how well the treatment destroys the leukaemia cells.
At a glance
What is this study about?
Acute lymphoblastic leukaemia (ALL) affects white blood cells called lymphocytes. In B-precursor ALL, the body produces too many immature B-cells, which crowd out normal, healthy blood cells. While initial treatment often clears the disease, the leukaemia can sometimes return. When cancer comes back, it is known as a relapse, and doctors often look for newer, more powerful combinations of treatments to help.
This study tests two targeted medicines called veltuzumab and epratuzumab alongside intensive chemotherapy. These medicines are monoclonal antibodies, which are laboratory-made proteins designed to seek out specific targets on the surface of B-cells (known as CD20 and CD22). By latching onto these targets, the drugs aim to help destroy cancer cells while sparing as much healthy tissue as possible.
Because this is a Phase I/II trial, the main goal is to find out if giving one or both of these antibodies alongside standard chemotherapy is safe. Doctors want to see what side effects occur, find the best and safest doses, and observe whether the combination helps put the leukaemia back into complete remission.
Taking part in this research helps doctors learn whether adding targeted therapies can improve survival and quality of life for people facing relapsed blood cancer. The results could help shape future standard treatments across the NHS.
Key takeaways
- Tests two targeted antibodies (veltuzumab and epratuzumab) with strong chemotherapy.
- Aimed at people aged 16 to 65 with a first return of B-cell acute lymphoblastic leukaemia.
- Primary focus is checking safety, finding the right doses, and measuring cancer response.
- Requires hospital visits and stays for intensive treatment and close monitoring.
- Participation is completely voluntary and you can stop at any time.
Who may be eligible?
You may be able to join this study if you are between 16 and 65 years old and have been diagnosed with a first relapse of B-cell acute lymphoblastic leukaemia. Your earlier period without cancer (remission) must have lasted for at least six months. You also need to be reasonably active and well enough to cope with strong chemotherapy.
Because intensive cancer treatments put extra demands on the body, your heart, kidneys, and liver must be working well. Doctors will carry out blood tests and heart scans to confirm this. Women who could become pregnant must have a negative pregnancy test, and all participants must agree to use reliable contraception during the trial.
You will not be able to join if your leukaemia carries a specific genetic change known as the Philadelphia chromosome, or if your cancer has returned more than once. The trial is also not suitable for people who have already had chemotherapy for this relapse (apart from a short course of steroids), those who have received radiotherapy to the chest, or people with serious, uncontrolled conditions like severe diabetes or heart disease.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am between 16 and 65 years of age.
- I have B-cell acute lymphoblastic leukaemia that has returned for the first time.
- My previous remission lasted for at least 6 months.
- I am generally active and well enough to receive strong chemotherapy.
- My leukaemia is not Philadelphia chromosome positive.
- I have not had radiotherapy to my chest in the past.
What does participation involve?
If you take part, your treatment will involve regular visits to the hospital. You will receive standard intensive chemotherapy along with one or both of the trial antibodies (veltuzumab and epratuzumab), which are given as drips into a vein. Because chemotherapy for relapsed leukaemia is intensive, you will likely need to spend some time staying on a hospital ward. Throughout your care, you will have regular blood tests, physical checks, heart scans, and bone marrow samples to track how the treatment is working and monitor your safety. The active treatment usually lasts several weeks to months, followed by regular outpatient check-ups to monitor your recovery.
Potential risks and benefits
Locations (1)
- Centre for Experimental Cancer MedicineCity onlyLondon, England
Common questions
What are monoclonal antibodies?
They are specially designed proteins made in a laboratory. They act like natural antibodies in your immune system, seeking out and attaching to specific targets on cancer cells.
Will I have to stay overnight in hospital?
Yes, intensive chemotherapy for relapsed leukaemia usually requires hospital stays so the medical team can support you and manage any side effects.
What happens if the treatment causes bad side effects?
Your doctors can pause or adjust your treatment doses, give supportive medicines to help you feel better, or stop the study treatment completely if it is not safe for you.
Can I leave the study if I change my mind?
Yes. Joining is entirely your choice. You can withdraw at any point, and your doctors will continue to give you the best available standard treatment.
Will taking part cost me anything?
No, the trial medicines and tests are provided as part of the clinical study within the hospital, though you may want to ask about help with travel costs.
How to find out more
Joanne Meerabux
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.